
About Saroja Pharma
Saroja Pharma is a publicly listed company based in India founded in 2019. Specialty chemical trader, exporter, and supplier that offers a range of products, with a focus on pharmaceutical ingredients. Its Indian entity Saroja Pharma Industries India Limited reported revenue of βΉ70.24 Cr. Saroja Pharma offers products and services including Specialty Chemicals, Pharma API, and Pharma Intermediates. Its focus areas include Pharmaceutical Distributors and Active Pharmaceutical Ingredients. Its competitors include Del Trade, Globofarm International and HUFORT HEALTHCARE.
Company details
Saroja Pharma Industries India Ltd was founded in 2019 in India. Specialty chemicals, including pharmaceutical ingredients, are traded, exported, and supplied by the company. A range of products is provided to meet industry needs. Operations emphasize ethical practices, equal opportunity, and a harassment-free workplace. Corporate governance is upheld through transparency and accountability in all dealings.
- Headquarters India
- Stage Public
- SectorsHealthcare
- Website sarojapharma.com
- Legal Name Saroja Pharma Industries India Ltd.
- Market Cap₹14.51 Cr
SAROJA-SM · NSE
- Share Price₹34.30
-4.99% today
- Revenue₹70.13 Cr
FY 2025-26 · +30.5% YoY
- EBITDA₹3.73 Cr
Margin 5.3%
- Net Profit₹1.68 Cr
FY 2025-26 · +61.5% YoY
- P/E (TTM)9.1x
P/B 0.9x
- ROE9.8%
ROCE 13.1%
- Debt / Equity0.72
Interest cover 41.2x
Associated legal entities of Saroja Pharma
Saroja Pharma operates through Saroja Pharma Industries India Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Saroja Pharma Industries India Limited Listed CIN U24110MH2019PLC319508 | Active | 14 Jan 2019 | Mumbai, Maharashtra | ₹70.2 Cr | 11 | View details |
Products & Services of Saroja Pharma
Saroja Pharma offers a comprehensive portfolio of products and services, including Specialty Chemicals, Pharma API, and Pharma Intermediates.
Trading and supplying effective specialty chemicals for various industries.
Active ingredients for drug manufacturing and export.
Intermediate compounds used in pharma production processes.
Board of directors of Saroja Pharma Industries India Limited (Saroja Pharma)
Saroja Pharma Industries India Limited is the primary company behind Saroja Pharma. The board of Saroja Pharma Industries India Limited currently have 8 directors; the longest-serving is Biju Gopinathan Nair, appointed in 2019. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Biju Gopinathan Nair DIN 08330223 | Managing Director | 14 Jan 2019 | 7 yrs 10 mo | Saroja Pharma Industries India Limited |
| Manish Dasharath Kamble DIN 08330224 | Whole-time director | 14 Jan 2019 | 7 yrs 10 mo | Saroja Pharma Industries India Limited |
| Pulinattu Nandakumar DIN 09852465 | Director | 02 Feb 2023 | 3 yrs 9 mo | Saroja Pharma Industries India Limited |
| Pinky Kataruka DIN 08139054 | Director | 05 May 2023 | 3 yrs 6 mo | Saroja Pharma Industries India Limited |
| Sonal Jain DIN 10153892 | Director | 09 May 2023 | 3 yrs 6 mo | Saroja Pharma Industries India Limited |
| Anita Sethia DIN 08956503 | Director | 03 Sep 2025 | 1 yr 2 mo | Saroja Pharma Industries India Limited |
| Santosh Shivram Palav DIN 00349518 | Additional Director | 09 Oct 2025 | 1 yr 1 mo | Saroja Pharma Industries India Limited |
| Ravindra Shivaji Salaskar DIN 11315910 | Whole-time director | 09 Oct 2025 | 1 yr 1 mo | Saroja Pharma Industries India Limited |
IPO & Listings of Saroja Pharma
Saroja Pharma is a publicly listed company on the NSE with ticker symbol SAROJA in India, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Sep 2023
- Listed onNSE: SAROJA
- Listed entitySaroja Pharma Industries India Ltd.
- Exchange sectorDistribution services
- ISININE0PCL01011
- Share price₹40.80 (+4.88% on the day) · 2026-09-30
- Market capitalisation₹16.4 Cr
- Price to earnings10.2
- EPS (diluted, trailing year)₹4.02
- Volume (last session)1,600
Financials of Saroja Pharma
Exchange-reported figures of Saroja Pharma Industries India Limited, the listed company behind Saroja Pharma (NSE: SAROJA-SM).
Financial Highlights
FY 2025-26 Β· StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 70.13 | 53.73 | 40.67 | 50.19 | 55.63 | 36.66 |
| Revenue growth | +30.5% | +32.1% | -19.0% | -9.8% | +51.8% | - |
| EBITDA | 3.73 | 2.79 | 2.57 | 2.72 | 2.09 | 1.31 |
| EBITDA margin | +5.3% | +5.2% | +6.3% | +5.4% | +3.8% | +3.6% |
| Profit before tax | 2.24 | 1.46 | 1.22 | 1.49 | 1.56 | 1.05 |
| Net profit | 1.68 | 1.04 | 0.89 | 1.06 | 1.12 | 0.75 |
| Net profit margin | +2.4% | +1.9% | +2.2% | +2.1% | +2.0% | +2.1% |
| EPS (βΉ) | 4.02 | 2.57 | 2.18 | 3.61 | 50.49 | 731.30 |
| Balance sheet | ||||||
| Total assets | 31.70 | 25.13 | 20.38 | 15.28 | 10.16 | 3.95 |
| Net worth | 17.29 | 15.68 | 14.64 | 5.09 | 4.03 | 0.94 |
| Total debt | 14.41 | 9.46 | 5.73 | 10.18 | 6.14 | 3.02 |
| Cash & bank | 0.34 | 0.33 | 0.32 | 0.36 | 0.26 | 0.00 |
| Net working capital | 8.51 | 12.81 | 11.43 | 10.10 | 9.75 | 3.83 |
| Cash flow | ||||||
| Cash from operations | 7.44 | 1.15 | 1.02 | 2.19 | (3.67) | (1.05) |
| Cash from investing | (11.68) | (2.70) | (4.76) | (4.82) | (0.34) | (0.05) |
| Cash from financing | 4.25 | 1.56 | 3.70 | 2.73 | 4.27 | 1.03 |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 70.13 | 53.73 | 40.67 | 50.19 | 55.63 | 36.66 |
| Revenue growth | +30.5% | +32.1% | -19.0% | -9.8% | +51.8% | - |
| Other income | 0.11 | 0.19 | 0.19 | 0.16 | 0.32 | 0.09 |
| Total expenses | 66.40 | 50.94 | 38.10 | 47.47 | 53.54 | 35.35 |
| Employee cost | 0.69 | 0.74 | 0.92 | 0.83 | 0.73 | 0.55 |
| EBITDA | 3.73 | 2.79 | 2.57 | 2.72 | 2.09 | 1.31 |
| EBITDA margin | +5.3% | +5.2% | +6.3% | +5.4% | +3.8% | +3.6% |
| Depreciation | 0.11 | 0.11 | 0.09 | 0.07 | 0.05 | 0.02 |
| Interest | 1.49 | 1.41 | 1.45 | 1.32 | 0.80 | 0.33 |
| Profit before tax | 2.24 | 1.46 | 1.22 | 1.49 | 1.56 | 1.05 |
| Tax | 0.62 | 0.42 | 0.33 | 0.43 | 0.44 | 0.30 |
| Net profit | 1.68 | 1.04 | 0.89 | 1.06 | 1.12 | 0.75 |
| Net profit margin | +2.4% | +1.9% | +2.2% | +2.1% | +2.0% | +2.1% |
| EPS (βΉ) | 4.02 | 2.57 | 2.18 | 3.61 | 50.49 | 731.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 4.02 | 4.02 | 4.02 | 2.94 | 0.23 | 0.01 |
| Reserves & surplus | 13.27 | 11.66 | 10.62 | 2.15 | 3.80 | 0.93 |
| Shareholders' funds (net worth) | 17.29 | 15.68 | 14.64 | 5.09 | 4.03 | 0.94 |
| Secured loans | 6.10 | 8.48 | 3.79 | 8.00 | 5.13 | 1.60 |
| Unsecured loans | 8.31 | 0.98 | 1.94 | 2.18 | 1.01 | 1.42 |
| Total debt | 14.41 | 9.46 | 5.73 | 10.18 | 6.14 | 3.02 |
| Total liabilities | 31.70 | 25.13 | 20.38 | 15.28 | 10.16 | 3.95 |
| Assets | ||||||
| Gross block | 2.90 | 2.84 | 2.74 | 2.36 | 0.42 | 0.12 |
| Net block | 2.18 | 2.50 | 2.51 | 2.22 | 0.35 | 0.09 |
| Capital work in progress | 20.34 | 8.61 | 6.13 | 1.79 | 0.00 | 0.00 |
| Investments | 0.54 | 0.34 | 0.20 | 0.14 | 0.04 | 0.00 |
| Inventories | 0.86 | 0.10 | 0.40 | 3.87 | 0.47 | 0.66 |
| Sundry debtors | 17.30 | 26.58 | 16.24 | 11.11 | 13.98 | 7.22 |
| Cash & bank balances | 0.34 | 0.33 | 0.32 | 0.36 | 0.26 | 0.00 |
| Loans & advances | 0.06 | 0.21 | 0.64 | 0.81 | 0.38 | 0.22 |
| Total current assets | 18.56 | 27.22 | 17.60 | 16.15 | 15.09 | 8.10 |
| Total current liabilities | 10.05 | 14.41 | 6.17 | 6.05 | 5.34 | 4.27 |
| Net working capital | 8.51 | 12.81 | 11.43 | 10.10 | 9.75 | 3.83 |
| Total assets | 31.70 | 25.13 | 20.38 | 15.28 | 10.16 | 3.95 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 0.33 | 0.32 | 0.36 | 0.26 | 0.00 | 0.08 |
| Net cash from operating activities | 7.44 | 1.15 | 1.02 | 2.19 | (3.67) | (1.05) |
| Net cash from investing activities | (11.68) | (2.70) | (4.76) | (4.82) | (0.34) | (0.05) |
| Net cash from financing activities | 4.25 | 1.56 | 3.70 | 2.73 | 4.27 | 1.03 |
| Net change in cash | 0.01 | 0.01 | (0.04) | 0.10 | 0.26 | (0.07) |
| Closing cash | 0.34 | 0.33 | 0.32 | 0.36 | 0.26 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +30.5% | +32.1% | -19.0% | -9.8% | +51.8% | - |
| EBITDA growth | +33.7% | +8.6% | -5.5% | +30.1% | +59.5% | - |
| PBT growth | +53.4% | +19.7% | -18.1% | -4.5% | +48.6% | +9997.0% |
| Net income growth | +61.5% | +16.9% | -16.0% | -5.4% | +49.3% | - |
| Revenue CAGR (3Y) | +11.8% | -1.2% | +3.5% | - | - | - |
| EBITDA CAGR (3Y) | +11.1% | +10.1% | +25.2% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +2.3% | +1.9% | +2.2% | +2.1% | +2.0% | +2.1% |
| Return on capital employed | +13.1% | +12.6% | +14.9% | +22.1% | +33.7% | +34.3% |
| Return on net worth | +9.8% | +6.8% | +8.9% | +23.3% | +45.9% | +77.7% |
| Debt / equity | 0.72 | 0.50 | 0.81 | 1.79 | 1.84 | 3.21 |
| Long-term debt / equity | 0.27 | 0.13 | 0.28 | 0.49 | 0.63 | 1.51 |
| Interest cover | 41.16 | 52.61 | 58.47 | 49.81 | 39.22 | 25.58 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 24.44 | 19.26 | 15.95 | 36.11 | 206.04 | 305.50 |
| Inventory turnover | 146.10 | 214.92 | 19.05 | 23.13 | 98.46 | 55.55 |
| Debtors turnover | 3.20 | 2.51 | 2.97 | 4.00 | 5.25 | 5.08 |
| EPS (βΉ) | 4.02 | 2.57 | 2.18 | 3.61 | 50.49 | 731.30 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 43.00 | 38.99 | 36.42 | 17.33 | 178.30 | 935.90 |
Competitors of Saroja Pharma
Saroja Pharma has 3 listed competitors in our database. They include Del Trade, Globofarm International and HUFORT HEALTHCARE.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| deltrade.in | 2010 | Delhi, India | 76 | Serves as a distributor of a wide range of pharmaceutical drugs. | ||
| globofarm.net | 2014 | Mumbai, India | Manufactures and supplies pharmaceutical ingredients and wellness products worldwide. | |||
| hufort.in | 2007 | Mumbai, India | 6 | Distributes pharmaceutical raw materials through import, stock, and sales services. |
Detailed competitors of Saroja Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Saroja Pharma
Complete news archive for Saroja Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Saroja Pharma
Saroja Pharma was founded in 2019.
Saroja Pharma is headquartered in India.
The primary company behind Saroja Pharma, Saroja Pharma Industries India Limited, reported revenue of βΉ70.24 Cr for FY 2026, up 31% year on year.
Saroja Pharma Industries India Ltd was founded in 2019 in India. Specialty chemicals, including pharmaceutical ingredients, are traded, exported, and supplied by the company. A range of products is provided to meet industry needs. Operations emphasize ethical practices, equal opportunity, and a harassment-free workplace. Corporate governance is upheld through transparency and accountability in all dealings.
Saroja Pharma's top competitors include Del Trade, Globofarm International and HUFORT HEALTHCARE.
Saroja Pharma offers Specialty Chemicals, Pharma API, and Pharma Intermediates.
Yes, Saroja Pharma is publicly traded on NSE under the ticker symbol SAROJA.
Saroja Pharma operates through Saroja Pharma Industries India Limited.
The legal entities of Saroja Pharma currently have 10 directors, including Anita Sethia, Pulinattu Nandakumar, Yogita Maheshwari and others.
